10,002 results match your criteria common myeloid


Myeloid/lymphoid neoplasms with FLT3 rearrangement.

Mod Pathol 2021 May 14. Epub 2021 May 14.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Myeloid/lymphoid neoplasms (M/LN) with 13q12/FLT3 rearrangement have been suggested as candidates for possible inclusion in the World Health Organization classification group of M/LN with eosinophilia (M/LN-eo). We report 12 patients with confirmed FLT3 rearrangement, six with t(12;13)/ETV6-FLT3; one with ins(13;22)/BCR-FLT3; and five with an unconfirmed partner gene located on chromosome bands 2p16, 3q27, 5q15, 5q35, and 7q36. Disease presentations were heterogeneous, including lymphoblastic leukemia/lymphoma, myeloid sarcoma, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome. Read More

View Article and Full-Text PDF

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review.

Am J Dermatopathol 2021 May 11. Epub 2021 May 11.

Medical Student, College of Medicine, Texas A&M Health Science Center, Houston, TX; Resident Physician, Department of Pathology, Baylor Scott and White Medical Center, Temple, TX; Intern, Department of Internal Medicine, University of Texas Austin Dell Medical School, Austin, TX; Clinical Assistant Professor, Department of Dermatology, Baylor Scott and White Medical Center, Temple, TX; and Clinical Associate Professor, Department of Dermatology and Pathology, Baylor Scott and White Medical Center, Temple, TX.

Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that frequently has cutaneous manifestations. The diagnosis can be a challenge because of its heterogenous clinical presentation, ranging from a brown or violaceous solitary nodule or patch to mixed, disseminated lesions. Furthermore, BPDCN tumor cells express immunohistochemical markers in common with acute myeloid leukemia, which can lead to misdiagnosis. Read More

View Article and Full-Text PDF

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions.

Am Soc Clin Oncol Educ Book 2021 Mar;41:1-20

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. Read More

View Article and Full-Text PDF

Germline risk of clonal haematopoiesis.

Nat Rev Genet 2021 May 13. Epub 2021 May 13.

Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.

Clonal haematopoiesis (CH) is a common, age-related expansion of blood cells with somatic mutations that is associated with an increased risk of haematological malignancies, cardiovascular disease and all-cause mortality. CH may be caused by point mutations in genes associated with myeloid neoplasms, chromosomal copy number changes and loss of heterozygosity events. How inherited and environmental factors shape the incidence of CH is incompletely understood. Read More

View Article and Full-Text PDF

Common clonal origin of chronic myelomonocytic leukemia and B cell acute lymphoblastic leukemia in a patient with a germline variant.

Cold Spring Harb Mol Case Stud 2021 May 13. Epub 2021 May 13.

McGill University.

Hematological malignancies are broadly divided into myeloid and lymphoid neoplasms, reflecting the two major cellular lineages of the hematopoietic system. It is generally rare for hematological malignancies to spontaneously progress with a switch from myeloid to lymphoid lineage. We describe the exceptional case of a patient who sequentially developed myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and B cell acute lymphoblastic leukemia (B-ALL), as well as our investigation into the underlying pathogenesis. Read More

View Article and Full-Text PDF

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:
Lin Cheng

Front Pharmacol 2021 26;12:588063. Epub 2021 Apr 26.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.

Adverse drug reactions are a public health issue that draws widespread attention, especially for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) which have high mortality and lack of efficacious treatment. Though T-cell-mediated HLA-interacted immune response has been extensively studied, our understanding of the mechanism is far from satisfactory. This review summarizes infection (virus, bacterial, and mycoplasma infection), an environmental risk factor, as a trigger for SJS/TEN. Read More

View Article and Full-Text PDF

[Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].

Zhonghua Xue Ye Xue Za Zhi 2021 Apr;42(4):288-294

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.

To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese patients with acute myeloid leukemia (AML) who are unable to tolerate intensive induction chemotherapy. Adults ≥ 18 years with newly diagnosed AML who were ineligible for intensive chemotherapy were enrolled in this international, randomized, double-blind, placebo-controlled trial. Globally, patients (=211) were randomized 2∶1 to either venetoclax with LDAC or placebo with LDAC in 28-d cycles, with LDAC on days 1-10. Read More

View Article and Full-Text PDF

Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.

Clin Lab 2021 May;67(5)

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder, which is caused by BCR-ABL fusion that has tyrosine kinase activity. The emergence of the first generation of tyrosine kinase inhibitors increased survival in patients. CML patients remain in silent phase for a long time by using drugs such as imatinib. Read More

View Article and Full-Text PDF

Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.

Am J Clin Pathol 2021 May 12. Epub 2021 May 12.

Division of Hematopathology, Mayo Clinic College of Medicine, Rochester, MN, USA.

Objectives: SF3B1 mutations are the most common mutations in myelodysplastic syndromes (MDS). The International Working Group for the Prognosis of MDS (IWG-PM) recently proposed SF3B1-mutant MDS (SF3B1-mut-MDS) as a distinct disease subtype. We evaluated the spectrum and molecular landscape of SF3B1-mutated myeloid disorders and assessed the prognostication in MDS harboring SF3B1 mutations (MDS-SF3B1). Read More

View Article and Full-Text PDF

Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.

Respirol Case Rep 2021 Jun 7;9(6):e00753. Epub 2021 May 7.

Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan.

Dasatinib is a potent and effective second-generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib-resistant or imatinib-intolerant breakpoint cluster region-Abelson (BCR-ABL)-positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome-positive acute lymphocytic leukaemia. The most common adverse events associated with dasatinib therapy are skin rash, gastrointestinal upset, pancytopenia, pulmonary hypertension, and fluid retention, including pleural effusion. However, chylothorax secondary to dasatinib administration has rarely been reported. Read More

View Article and Full-Text PDF

Prostaglandin E Enhances Aged Hematopoietic Stem Cell Function.

Stem Cell Rev Rep 2021 May 11. Epub 2021 May 11.

Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, 980 West Walnut St, Indianapolis, IN, 46202, USA.

Aging of hematopoiesis is associated with increased frequency and clonality of hematopoietic stem cells (HSCs), along with functional compromise and myeloid bias, with donor age being a significant variable in survival after HSC transplantation. No clinical methods currently exist to enhance aged HSC function, and little is known regarding how aging affects molecular responses of HSCs to biological stimuli. Exposure of HSCs from young fish, mice, nonhuman primates, and humans to 16,16-dimethyl prostaglandin E (dmPGE) enhances transplantation, but the effect of dmPGE on aged HSCs is unknown. Read More

View Article and Full-Text PDF

Clinicopathological Evaluation of Acute Leukemias in a Tertiary Care Hospital: A Cross-Sectional Study.

Turk Patoloji Derg 2021 ;37(2):145-153

Department of Pathology, Krishna Institute of Medical Sciences (Deemed to University), MAHARASHTRA, INDIA.

Objective: Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) are clinically and biologically diverse phenotypic diseases amongst hematological malignancies. The current study objectives were to diagnose and classify cases of AL as per revised 4th edition of WHO 2016 classification of AL's and study their clinicopathological profiles.

Material And Method: This cross-sectional, observational study included 68 patients, diagnosed with AL were recruited. Read More

View Article and Full-Text PDF
January 2021

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL.

medRxiv 2021 May 5. Epub 2021 May 5.

Background: Severe COVID-19 pneumonia results from a hyperinflammatory immune response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of myeloid cells, leading to elevation of downstream inflammatory chemokines (MCP-1, IL-8, IP-10), cytokines (IL-6, IL-1), and other markers of systemic inflammation (CRP, D-dimer, ferritin). CS leads to fever, hypotension, coagulopathy, respiratory failure, ARDS, and death. Lenzilumab is a novel Humaneered anti-human GM-CSF monoclonal antibody that directly binds GM-CSF and prevents signaling through its receptor. Read More

View Article and Full-Text PDF

Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.

Hematology 2021 Dec;26(1):371-379

Department of Hematology, Chinese PLA General Hospital, Beijing, People's Republic of China.

Objectives: The outcome of elderly acute myeloid leukemia (AML) patients is poor, which was traditionally attributed to patient- and leukemia-related factors. However, studies about the genetic features of these elderly patients have not been integrated and the genetic mechanism of their poor outcome is less known.

Methods: Here, we used next generation sequencing (NGS) to identify the genetic features of elderly AML patients and confirmed the efficacy of chemotherapy based on molecular aberrations. Read More

View Article and Full-Text PDF
December 2021

It takes a village: microbiota, parainflammation, paligenosis and bystander effects in colorectal cancer initiation.

Dis Model Mech 2021 May 10;14(5). Epub 2021 May 10.

Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Sporadic colorectal cancer (CRC) is a leading cause of worldwide cancer mortality. It arises from a complex milieu of host and environmental factors, including genetic and epigenetic changes in colon epithelial cells that undergo mutation, selection, clonal expansion, and transformation. The gut microbiota has recently gained increasing recognition as an additional important factor contributing to CRC. Read More

View Article and Full-Text PDF

The Prenatal Origin of Childhood Leukemia: Potential Applications for Epidemiology and Newborn Screening.

Front Pediatr 2021 23;9:639479. Epub 2021 Apr 23.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

Childhood leukemias are heterogeneous diseases with widely differing incident rates worldwide. As circulating tumors, childhood acute leukemias are uniquely accessible, and their natural history has been described in greater detail than for solid tumors. For several decades, it has been apparent that most cases of childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) initiate . Read More

View Article and Full-Text PDF

Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.

Front Immunol 2021 21;12:666935. Epub 2021 Apr 21.

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. While initially restricted to the skin, malignant cells can appear in blood, bone marrow and secondary lymphoid organs in later disease stages. However, only little is known about phenotypic and functional properties of malignant T cells in relationship to tissue environments over the course of disease progression. Read More

View Article and Full-Text PDF

Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.

Leukemia 2021 May 9. Epub 2021 May 9.

Division of Hematological Malignancy, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.

Chromosome translocations involving the MLL gene are common rearrangements in leukemia. Such translocations fuse the MLL 5'-region to partner genes in frame, producing MLL-fusions that cause MLL-related leukemia. MLL-fusions activate transcription of target genes such as HoxA cluster and Meis1, but the underlying mechanisms remain to be fully elucidated. Read More

View Article and Full-Text PDF

A Rare Anatomic Variant of Double Replaced Hepatic Arteries: A Case Report and Brief Review of the Anomalous Hepatic Vasculature Literature.

Am J Case Rep 2021 May 9;22:e930990. Epub 2021 May 9.

Division of Surgical Oncology, Department of Surgery, University of Toledo Medical Center, Toledo, OH, USA.

BACKGROUND The liver is a frequent site of surgical resection for both benign and malignant lesions. Advanced knowledge of the hepatic arterial system and its variants is crucial to avoid incidental injuries during a resection procedure. Many variants have been previously described in the literature, yet extremely rare cases continue to be encountered in clinical practice. Read More

View Article and Full-Text PDF

Isolated Extramedullary Relapse After Human Leukocyte Antigen-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Case Reports and Literature Review.

Transplant Proc 2021 May 4. Epub 2021 May 4.

Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, Thailand. Electronic address:

Isolated extramedullary relapse (iEMR) of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare and has a dismal prognosis. Among 67 patients with AML after allo-HSCT, iEMR and bone marrow relapse occurred in 6% and 20.9%, respectively, with a median time to relapse of 11. Read More

View Article and Full-Text PDF

Circulating CD15 LOX-1 PMN-MDSCs are a potential biomarker for the early diagnosis of non-small cell lung cancer.

Int J Clin Pract 2021 May 6:e14317. Epub 2021 May 6.

Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.

Aims: Non-small-cell lung cancer (NSCLC) is the most common clinical lung cancer. Polymorphonuclear-myeloid derived suppressor cells (PMN-MDSCs), which are the major population of MDSCs, are involved in NSCLC progression. Recently, it was found that lectin-type oxidized LDL receptor 1 (LOX-1) could identify human PMN-MDSCs. Read More

View Article and Full-Text PDF

Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report.

J Med Case Rep 2021 May 7;15(1):228. Epub 2021 May 7.

Division of Pediatric Hematology and Oncology, Department of Pediatrics, Penn State College of Medicine and Penn State Children's Hospital, 500 University Drive, Mail Code H085, Hershey, PA, USA.

Background: Acute myeloid leukemia (AML) is a disease with a significant amount of cytogenetic heterogeneity including mixed-lineage leukemia (MLL) gene rearrangements. Pediatric AML commonly has genetic rearrangements which involve chromosome 11q23 in 15-20% of cases, and these genetic abnormalities have been associated with a poorer prognosis (Grimwade et al. in Blood 92:2322-2333, 1998; Raimondi et al. Read More

View Article and Full-Text PDF

Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.

Leuk Res 2021 Apr 30;107:106603. Epub 2021 Apr 30.

Laboratory of Clinical and Experimental Immunology, Healthy and Life Science School Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil. Electronic address:

Acute Myeloid Leukemia (AML) is a complex and highly aggressive disease. To characterize the prognostic factors of pediatric patients with AML relapse, a retrospective cohort study was performed to collect data from children and adolescents, at a hematological oncology reference center, over 11 years. We selected 51 cases of the disease, diagnosed and treated uniformly, divided into two groups: with complete remission (n = 33; 65 %) and with relapse (n = 18; 35 %). Read More

View Article and Full-Text PDF

Gene knockout in highly purified mouse hematopoietic stem cells by CRISPR/Cas9 technology.

J Immunol Methods 2021 May 4;495:113070. Epub 2021 May 4.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China. Electronic address:

The CRISPR/Cas9 system has been used for genome editing of human and mouse cells. In this study, we established a protocol for gene knockout (KO) in mouse hematopoietic stem cells (HSCs). HSCs were highly purified from the bone marrow of tamoxifen-treated Cas9-EGFP/Cre-ER transgenic mice, maintained in serum-free polyvinyl alcohol culture with cytokines, lentivirally transduced with sgRNA-Crimson, and transplanted into lethally irradiated mice with competitor cells. Read More

View Article and Full-Text PDF

Therapeutic cancer vaccine therapy for acute myeloid leukemia.

Immunotherapy 2021 May 6. Epub 2021 May 6.

Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.

Antitumor function of the immune system has been harnessed to eradicate tumor cells as cancer therapy. Therapeutic cancer vaccines aim to help immune cells recognize tumor cells, which are difficult to target owing to immune escape. Many attempts at vaccine designs have been conducted throughout the last decades. Read More

View Article and Full-Text PDF

Allogeneic hematopoietic stem cell transplantation overcomes the poor prognosis in MLL-rearranged solid tumor therapy related-acute myeloid leukemia.

Am J Cancer Res 2021 15;11(4):1683-1696. Epub 2021 Apr 15.

Department of Hematology, Nanfang Hospital, Southern Medical University Guangzhou, China.

MLL rearrangement is very common in solid tumor therapy-related acute myeloid leukemia (t-AML). To investigated the prognosis of solid tumor MLL t-AML, 157 patients were divided into 3 groups: non-MLL t-AML (n=41), MLL t-AML (n=18) and MLL de novo AML (n=98). Of the 150 patients underwent anti-leukemia therapy, the complete remission (CR) was similar in MLL t-AML, non-MLL t-AML and MLL de novo AML (P=0. Read More

View Article and Full-Text PDF

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers.

Cells 2021 Apr 30;10(5). Epub 2021 Apr 30.

Department of Obstetrics and Gynecology, Osaka Saiseikai Nakatsu Hospital, Osaka 530-0012, Japan.

Uterine cervical and endometrial cancers are the two most common gynecological malignancies. As demonstrated in other types of solid malignancies, an increased number of circulating or tumor-infiltrating myeloid-derived suppressor cells (MDSCs) have also been observed in uterine cervical and endometrial cancers, and increased MDSCs are associated with an advanced stage, a short survival, or a poor response to chemotherapy or radiotherapy. In murine models of uterine cervical and endometrial cancers, MDSCs have been shown to play important roles in the progression of cancer. Read More

View Article and Full-Text PDF

Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.

Ann Hematol 2021 May 4. Epub 2021 May 4.

Algemeen Ziekenhuis Sint-Jan Brugge, Brugge, Belgium.

Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016-2019) in Belgium (NCT03678454). Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were treated with ponatinib per current label. Read More

View Article and Full-Text PDF

IDH Inhibitors in AML-Promise and Pitfalls.

Curr Hematol Malig Rep 2021 Apr 30. Epub 2021 Apr 30.

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA.

Purpose Of Review: Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases. Mutations in IDH leads to abnormal epigenetic regulation in AML cells and blocks differentiation. Inhibitors of mutated IDH1 and IDH2, ivosidenib and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML; ivosidenib is also approved for newly diagnosed AML patients not fit for standard chemotherapy. Read More

View Article and Full-Text PDF